

## Fitzasovimab

Cat. No.:	HY-P99621
CAS No.:	2467411-25-0
Target:	CMV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Fitzasovimab (NPC-21; EV2038) is a fully human IgG1 $\lambda$ mAb against human cytomegalovirus (hCMV). Fitzasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fitzasovimab inhibits cell-to-cell transmission of hCMV <sup>[1]</sup> .
<b>In Vitro</b>	Fitzasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor <sup>[1]</sup> . Fitzasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates <sup>[1]</sup> . Fitzasovimab shows anti-hMCMV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC <sub>50</sub> s of 13-105 ng/mL and IC <sub>90</sub> s of 0.208-1.026 $\mu$ g/mL <sup>[1]</sup> . Fitzasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC <sub>90</sub> s of 13-19 $\mu$ g/mL <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11(6):707-716.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA